Pharmaceutical trials: When the Left’s obsession with race kills

Published



One of the last things Francis Collins, then-director of the National Institutes of Health, did before retiring was to pressure Moderna into delaying the release of its COVID-19 vaccine because he wanted more minorities in its clinical trials.

Moderna’s CEO, Stephane Bancel, was happy to oblige him, saying that diversity “matters more to us than speed.”

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.